CADL•benzinga•
Candel Therapeutics Announces Final Data From Both Prolonged Median Overall Survival And Long Tail Of Survival In Phase 2a Clinical Trial Of CAN-2409 In Advanced Non-Small Cell Lung Cancer Patients Non-Responsive to Immune Checkpoint Inhibitor Treatment
Summary
No summary available.
Original Article
Read the full article from the original source for complete details and context.
Read Full ArticleArticle published on March 26, 2025 by benzinga